title: Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer.
abstract: OBJECTIVE
  We investigated the prognostic significance of extracellular matrix metalloproteinase inducer (EMMPRIN) and matrix metalloproteinase 2 (MMP-2) in epithelial ovarian cancer as well as their relation to hyaluronan (HA) expression.
  
  
  METHODS
  The expression of EMMPRIN and MMP-2 was analyzed immunohistochemically in 295 primary epithelial ovarian cancer patients and 67 metastases.
  
  
  RESULTS
  A low membranous EMMPRIN expression was detected more often in serous tumors than in other types (p < 0.0005) and it was associated with tumors of advanced stage (p = 0.012) or with a large primary residual (p = 0.011). A low expression of MMP-2 in cancer cells was associated with a high histologic grade (grade 3) of the tumor (p = 0.005) and endometrioid type of tumors (p < 0.0005). Stromal MMP-2 expression was significantly associated with strong stromal HA expression (p = 0.002, r = 0.187). In univariate analysis, 10-year disease-related (DRS) and recurrence-free survivals were significantly better when MMP-2 expression in cancer cells was high (p = 0.0057 and p = 0.0467, respectively). DRS was also better when membranous EMMPRIN expression was high (p = 0.013). In multivariate analysis, strong MMP-2 in cancer cells (RR = 1.48, CI = 1.07-2.04, p = 0.017) indicated favorable DRS.
  
  
  CONCLUSIONS
  Our results show that EMMPRIN and MMP-2 in cancer cells are significant indicators of a favorable prognosis of epithelial ovarian cancer.
authors.affiliation: Institute of Clinical Medicine, Pathology and Forensic Medicine, University of Kuopio, Kuopio, Finland.
authors.forename: S
authors.initials: S
authors.lastname: Sillanpää
authors.forename: M
authors.initials: M
authors.lastname: Anttila
authors.forename: K
authors.initials: K
authors.lastname: Suhonen
authors.forename: K
authors.initials: K
authors.lastname: Hämäläinen
authors.forename: T
authors.initials: T
authors.lastname: Turpeenniemi-Hujanen
authors.forename: U
authors.initials: U
authors.lastname: Puistola
authors.forename: M
authors.initials: M
authors.lastname: Tammi
authors.forename: R
authors.initials: R
authors.lastname: Sironen
authors.forename: S
authors.initials: S
authors.lastname: Saarikoski
authors.forename: V-M
authors.initials: VM
authors.lastname: Kosma
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000737:chemistry / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D051926:Basigin / Q000032:analysis*; D002277:Carcinoma / Q000737:chemistry* / Q000401:mortality; D018269:Carcinoma, Endometrioid / Q000737:chemistry / Q000401:mortality; D002462:Cell Membrane / Q000737:chemistry; D018282:Cystadenocarcinoma, Mucinous / Q000737:chemistry / Q000401:mortality; D018284:Cystadenocarcinoma, Serous / Q000737:chemistry / Q000401:mortality; D018291:Cystadenoma, Mucinous / Q000737:chemistry / Q000401:mortality; D018293:Cystadenoma, Serous / Q000737:chemistry / Q000401:mortality; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D006820:Hyaluronic Acid / Q000032:analysis; D020778:Matrix Metalloproteinase 2 / Q000032:analysis*; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000032:analysis*; D010051:Ovarian Neoplasms / Q000737:chemistry* / Q000401:mortality; D011379:Prognosis; D016037:Single-Blind Method; D017154:Stromal Cells / Q000737:chemistry
chemical_list: C497886:BSG protein, human; D009363:Neoplasm Proteins; D051926:Basigin; D006820:Hyaluronic Acid; D020778:Matrix Metalloproteinase 2